re: Ann: Patrys Announces $12.5 Million Right... "Given the interest of Onyx in supporting this trial Patrys will not be actively seeking a licensing partner for PAT SM6 at this time."
Interesting - looks to me like Onyx/Amgen have put an exclusivity clause in with the IST ? ie. if Carfilzomib works in combination with PAT-SM6 more effectively we will take it out.
Ann: Patrys Announces $12.5 Million Rights Issue , page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1853666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable